Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results
Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38
Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom
Company’s validated test available in the UK following implementation of UKHSA CTDA Regulations
Co-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28
In addition to hosting a booth to promote its existing diagnostics products at the conference, the Company will also hold a press conference to introduce its upcoming at-home and point-of-care PCR device.
